Published in Int J Clin Oncol on June 14, 2008
Docetaxel: its role in current and future treatments for advanced gastric cancer. Gastric Cancer (2009) 1.00
Function of chloride intracellular channel 1 in gastric cancer cells. World J Gastroenterol (2012) 0.84
The prognostic significance of chemotherapy for stage IV gastric cancer patients: a single-institution experience. Surg Today (2011) 0.78
Global cancer statistics, 2002. CA Cancer J Clin (2005) 119.22
Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med (2008) 12.97
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med (2007) 12.62
S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol (2008) 11.07
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol (2006) 9.16
Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. J Clin Oncol (2005) 2.39
The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: five-year follow-up. Lancet (1994) 1.92
Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Clin Cancer Res (2006) 1.90
Chemotherapy of advanced gastric cancer. Cancer Treat Rev (2007) 1.50
Synergistic effects of docetaxel and S-1 by modulating the expression of metabolic enzymes of 5-fluorouracil in human gastric cancer cell lines. Int J Cancer (2006) 1.21
Current status and future prospects of chemotherapy for metastatic gastric cancer: a review. Gastric Cancer (2005) 1.12
Japanese nationwide post-marketing survey of S-1 in patients with advanced gastric cancer. Gastric Cancer (2005) 1.04
Simple combinations of 5-FU pathway genes predict the outcome of metastatic gastric cancer patients treated by S-1. Int J Cancer (2006) 0.98
Multi-institutional phase II study of S-1 monotherapy in advanced gastric cancer with pharmacokinetic and pharmacogenomic evaluations. Oncologist (2007) 0.95
Phase II study of a combination of irinotecan and S-1 in patients with advanced gastric cancer (OGSG0002). Oncology (2008) 0.92
Phase I/II study of S-1 combined with paclitaxel in patients with unresectable and/or recurrent advanced gastric cancer. Br J Cancer (2006) 0.92
The multidisciplinary management of gastrointestinal cancer. Multimodal treatment of gastric cancer. Best Pract Res Clin Gastroenterol (2007) 0.88
Cancer pharmacogenomics: progress and obstacles toward the goal. Int J Clin Oncol (2005) 0.75